Abstract:
PURPOSE: A specific drug transmission method of K-Ras mutant cell is provided to detect cancer caused by K-Ras mutant in initial, to be very useful for the treatment of cancer, thereby extending the survival rate of cancer patients. CONSTITUTION: A specific drug transmission method comprises: a step of treating DNA bonding domain of p53 and drug for transferring to cells, and a step of transferring drug to neighbored K-Ras mutant cell by endocytosis by the DNA bonding domain of p53.
Abstract:
PURPOSE: A chemical inhibitor for the bond between snail-p53 is provided to effectively treat K-Ras mutagenic cancer disease by inducing the revelation of the p-53 in K-Ras mutant cell strain. CONSTITUTION: A chemical inhibitor has a structure marked as a chemical formula 1. In the chemical formula 1, m is an integer of 0-10, n and p is 0 or 1. In the chemical formula 1, Z is selected from a group comprising NH(CH2)qCH3, -OH, 4-phenylpiperidine group, isobutylamine, and isobutyloxy group and q is integer of 0-9. A pharmaceutical composition for treating cancer disease contains a compound for inhibiting the bond of snail-p53 as an active ingredient.
Abstract:
PURPOSE: A pharmaceutical composition for preventing or treating aging-related diseases and a method for screening a binding inhibitor are provided to effectively treat or prevent diseases caused by progerin and to specifically select a drug which suppresses binding between progerin and lamin A. CONSTITUTION: A compound of chemical formula 1 or 2 or a pharmaceutically acceptable salt thereof is provided. A pharmaceutical composition for preventing or treating aging-related diseases contains the compound of chemical formula 1 or 2 or a pharmaceutically acceptable salt thereof as an active ingredient. A method for screening a therapeutic agent for treating aging-related diseases comprises the step of selecting candidate drugs which suppress binding between progerin and lamin A.
Abstract:
본 발명은 스네일-p53 간의 결합을 저해하는 화합물 및 이를 유효성분으로 함유하는 암질환 치료제에 관한 것으로, 상기 스네일-p53 간의 결합 저해제는 K-Ras 돌연변이 세포주에서 p53의 발현을 유도함으로써 췌장암, 폐암, 담관암 및 대장암과 같이 진단이나 치료가 용이하지 않은 K-Ras 돌연변이성 암질환을 효과적으로 치료하거나 예방할 수 있다.
Abstract:
PURPOSE: A compound which suppresses snail-p53 and a therapeutic agent for treating cancer are provided to induce p53 expression in K-ras mutant cell line and to effectively prevent or treat cancer. CONSTITUTION: A method for screening a therapeutic agent for treating K-ras mutagenic cancer comprises: a step of culturing snail and candidate drugs on a p53-fixed plate; a step of selecting a candidate drug which suppresses snail-p53 binding using ELISA reader. The therapeutic agent contains a compound which suppresses snail-p53 binding. A DNA binding domain specifically transfers a drug in K-ras mutant cells.
Abstract:
본 발명은 진세노사이드 Rg4 또는 진세노사이드 Rg2, Rg4, Rg6 및 Rh1 혼합물을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물에 관한 것이다. 상기 진세노사이드 Rg4 또는 진세노사이드 Rg2, Rg4, Rg6 및 Rh1 혼합물을 인간 모낭 모유두 세포에 처리하면, 모낭 형성과 성장을 유도할 수 있는 3차원 구체의 형성 및 크기 증가 효과가 우수하며, 모낭 세포 활성화와 재생에 중요한 Wnt/β-카테닌 신호전달 활성화 효과가 우수하고, 모낭 형성과 성장에 중요한 ALPL, VCAN, BMP2 및 FGF7 유전자의 발현량 증가 효과가 우수하여 탈모 방지 및 발모 촉진용 조성물로 유용하게 사용될 수 있다.
Abstract:
본발명은산사자의에틸아세테이트분획물또는 n-부탄올분획물을포함하는염증성질환의예방또는치료용조성물에관한것으로, 상기분획물은대식세포에서의 IL-6 및 NO 생성을저해하는활성및 인간각질형성세포에서의 IP-10, Rantes 및 MDC 생성을저해하는활성이우수하여염증성질환의예방또는치료용조성물, 또는, 염증성질환의예방또는개선용건강기능식품, 또는, 피부염증의예방또는개선용화장료조성물로유용하게사용될수 있다.
Abstract:
본발명은식물이구비되는양변기의물탱크덮개에관한것으로서, 더욱상세하게는패킹이형성된덮개부의관통홀에식물이결합되고, 상기식물이결합된덮개부의하단면에는다수개의받침컵이형성됨으로써, 상기받침컵에항시물이채워지는구조이기에물탱크내에물이줄어들어도식물에물을공급할수 있고, 물의공급이사용자의별도의조작없이편리하게이용할수 있으며, 화장실에서식물을재배할수 있으므로, 적절한식물의종류를선택함으로써악취를흡수하거나식물고유의향기를발생시킬수 있으며, 그에따라서화장실의환경을개선할수 있는특징이있다.